- Home
- AMRX
as 04-18-2025 1:30pm EST
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.4B | IPO Year: | N/A |
| Target Price: | $10.80 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.18 - $9.48 | Next Earning Date: | 05-02-2025 |
| Revenue: | $2,793,957,000 | Revenue Growth: | 16.73% |
| Revenue Growth (this year): | 10.49% | Revenue Growth (next year): | 7.00% |
Stock Insider Trading Activity of Amneal Pharmaceuticals Inc. (AMRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Gautam | AMRX | Director | Apr 1 '25 | Sell | $8.30 | 80,000 | $664,000.00 | 1,728,886 | |
| Patel Tushar Bhikhubhai | AMRX | 10% Owner | Mar 14 '25 | Sell | $8.35 | 5,000,000 | $41,750,000.00 | 48,578,209 | |
| Konidaris Tasos | AMRX | Executive Vice President & CFO | Mar 5 '25 | Sell | $8.91 | 100,000 | $891,000.00 | 621,882 | |
| BOYER ANDREW S | AMRX | Executive Vice President | Mar 5 '25 | Sell | $8.89 | 125,000 | $1,111,250.00 | 290,106 | |
| Alva Emily Peterson | AMRX | Director | Mar 5 '25 | Sell | $8.90 | 80,000 | $712,000.00 | 170,771 | |
| Daly Jason B. | AMRX | EVP, Chief Legal Officer | Mar 5 '25 | Sell | $8.81 | 90,000 | $792,159.60 | 79,542 | |
| Patel Gautam | AMRX | Director | Mar 3 '25 | Sell | $8.90 | 80,000 | $712,000.00 | 1,728,886 | |
| Patel Gautam | AMRX | Director | Feb 3 '25 | Sell | $8.14 | 80,000 | $651,200.00 | 1,728,886 |
Latest Amneal Pharmaceuticals Inc. News
AMRX Breaking Stock News: Dive into AMRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years
Business Wire
8 days ago
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
Business Wire
11 days ago
Amneal to Report First Quarter 2025 Results on May 2, 2025
Business Wire
12 days ago
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
Business Wire
16 days ago
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
Business Wire
18 days ago
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
Business Wire
a month ago
Amneal to Participate at Upcoming Investor Conference
Business Wire
2 months ago
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Compare AMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRX Amneal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.